Louisiana is exploring an arrangement under which the Pelican State would make a one-time, up-front payment to a drugmaker in return for an unlimited supply of hepatitis C treatments for the state’s Medicaid patients and prison population.
It’s a model that someday could be applied to pay for other drug treatments in Louisiana and other states. But the program must first pass regulatory hurdles. Also, success hinges on whether the model can help cure most of Louisiana’s estimated 73,000 people who suffer from hepatitis C while lowering the state’s costs.
The subscription model would allow the state to access an ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.